Pfizer starts mid-stage trial of Omicron-targeting vaccine

Pfizer Inc and its German partner BioNTech SE said on Wednesday they had started a mid-stage study of a modified bivalent COVID-19 vaccine which also targets an Omicron variant.

The company did not disclose which subvariant of Omicron the vaccine would be targetting.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)